Insider trade report
Open the filing on sec.gov
Citius Oncology, Inc. (CTOR)
Nasdaq: CTOR · Pharmaceutical Preparations · Cranford, NJ · filing with the SEC since 2021
The companyfiscal 2025, as filed
Revenuen/a
Net income-$24.8M-17.1%
Earnings per share$-0.34-9.7%
Operating cash flow-$5.5M-4446.6%
Cash$3.9M+3504282.1%
Debtn/a
Shareholders’ equity$44.9M-2.8%
Shares, diluted73.3M+7.7%
Return on equity-55.2%
The recordfrom its filings
Filings in 202650
Newest filingNov 12 · 4
Annual reportDec 23, 2025
Quarterly reportAug 14, 2026
Next report due10-K by Dec 29
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$46.1Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Annual report to shareholders
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.